Saturday, January 18, 2025 7:56:08 PM
Why would they hide if they have anything meaningful to share? That simply doesn’t make any sense. The reality is they don’t have any earth shattering news to share. They know that Oncovir and other such in licensing deals/partnerships will have no impact on the share price. There will be nothing meaningful to share on Flaskworks and reimbursement either, both of which won’t come online until 2026 at the earliest.
The only news that will help move the share price in a massive way and importantly keep it sustained will be a PR from big pharma saying they are partnering with NWBO and injecting capital (whether it’s dilutive or non dilutive doesn’t matter). Unfortunately, this is not happening in 2025 either. Instead, NWBO will announce a collaboration trial in isolation, announce a partnership with Oncovir, and the stock will be slammed given the lack of support from big pharma, immediate cash needs (hence ton of dilution), and no buyout/exit potential in the future!
Just wait and watch to see this play out! Or don’t give LP the opportunity to fool you again and sell at the UK approval spike before you get sucked into the waiting game again like a bag holder.
The only news that will help move the share price in a massive way and importantly keep it sustained will be a PR from big pharma saying they are partnering with NWBO and injecting capital (whether it’s dilutive or non dilutive doesn’t matter). Unfortunately, this is not happening in 2025 either. Instead, NWBO will announce a collaboration trial in isolation, announce a partnership with Oncovir, and the stock will be slammed given the lack of support from big pharma, immediate cash needs (hence ton of dilution), and no buyout/exit potential in the future!
Just wait and watch to see this play out! Or don’t give LP the opportunity to fool you again and sell at the UK approval spike before you get sucked into the waiting game again like a bag holder.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
